Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$13.1 million.

  • SAB Biotherapeutics' Free Cash Flow fell 10415.12% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.6 million, marking a year-over-year increase of 251.56%. This contributed to the annual value of -$34.6 million for FY2024, which is 3678.51% down from last year.
  • SAB Biotherapeutics' Free Cash Flow amounted to -$13.1 million in Q3 2025, which was down 10415.12% from -$7.2 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Free Cash Flow ranged from a high of $7.6 million in Q1 2021 and a low of -$13.5 million during Q4 2023
  • For the 5-year period, SAB Biotherapeutics' Free Cash Flow averaged around -$6.4 million, with its median value being -$7.2 million (2021).
  • As far as peak fluctuations go, SAB Biotherapeutics' Free Cash Flow crashed by 7206996.61% in 2021, and later soared by 8506.65% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Free Cash Flow (Quarter) stood at -$7.2 million in 2021, then soared by 76.9% to -$1.7 million in 2022, then plummeted by 707.91% to -$13.5 million in 2023, then rose by 29.06% to -$9.6 million in 2024, then tumbled by 36.11% to -$13.1 million in 2025.
  • Its Free Cash Flow stands at -$13.1 million for Q3 2025, versus -$7.2 million for Q2 2025 and -$7.8 million for Q1 2025.